Keynote on the Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer’s Disease

Neurimmune announced today that it will participate in the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in San Francisco, CA and virtually from November 29 to December 2, 2022. Professor Roger M. Nitsch, Neurimmune’s CEO & President, will be presenting a keynote lecture on the “Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer’s Disease” on Friday, December 2, at 9:00 a.m. Pacific Time.

Alzheimer’s disease - the leading cause of dementia in elderly people - is characterized by a decade-long build-up of a protein in brain known as amyloid. It can damage the brain’s nerve cells resulting in progressing deficits in memory, learning, orientation in space and time, language, and thoughtful planning. Amyloid is readily detectable in affected brains and its removal is a therapeutic objective in Alzheimer’s disease.

On a cellular level, the build-up of amyloid in brain can damage communications between neurons, lead to the breakdown of neuronal transport systems and the formation of neurofibrillary tangles consisting of abnormally phosphorylated tau proteins. Besides amyloid removal, lowering tau pathology is an objective in Alzheimer’s disease therapy.

Aducanumab, approved by the U.S. FDA in 2021, is the first of a class of amyloid clearing-drugs currently in late-stage development. These seek to modify Alzheimer’s disease by clearing brain amyloid and lowering tau pathology in the brain. Accumulating evidence from multiple therapies in development, including new data to be presented at CTAD, suggest that amyloid clearance and lowered tau pathology leads to slowing of clinical decline over time. In clinical trials, slowing of clinical decline extended over a broad range of critical brain functions including cognition, memory and orientation, resulting in desired effects on activities of daily living and self-determination for Alzheimer’s patients.

CTAD 2022 presentations and fora relating to amyloid clearing-drugs include:

Tuesday, November 29 (4.50pm Pacific Time)
Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind Parallel-Group, 18-Month Study Evaluating Lecanemab in Early Alzheimer’s Disease

Thursday, December 1 (9:20am Pacific Time)
CTAD Open Discussion: Anti Amyloid Phase 3 Results

Friday, December 2 (9:00am Pacific Time)
Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer’s Disease

Friday, December 2 (2.50pm Pacific Time)
Aducanumab and Lecanemab Label Insoluble, Fibrillar, Diffusible Aβ Aggregates in Aqueous Extract of Human Alzheimer Disease Brain